Bio-Techne Corp Stock Price, News & Analysis

ScaleReady has awarded a $150,000 G-Rex Grant to Immuneel Therapeutics to enhance CAR-T cell manufacturing in India. The grant aims to support process development for improving scalability and cost-effectiveness of production at Immuneel's 12,000 square foot GMP facility in Bengaluru. With India facing approximately 120,000 new blood cancer cases annually and 70,000 related deaths, Immuneel targets manufacturing nearly 200 drug products daily. The G-Rex Grant Program, which has increased from $20M to $30M in total funding, has awarded 200 grants with over 50 applications pending. Recipients can receive up to $300,000 and access support from ScaleReady's consortium of partners specializing in cGMP manufacturing, quality control, and CGT business operations.

Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in three major upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference on June 3 at 2:40 PM CDT, the Jefferies Global Healthcare Conference on June 4 at 3:45 PM EDT, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 10:40 AM EDT. Investors can access live webcasts of all presentations through Bio-Techne's Investor Relations website.

ScaleReady has awarded $1,025,000 in G-Rex Grants to researchers at USC and Children's Hospital of Los Angeles (CHLA) to advance cell and gene therapy initiatives. The grants were distributed among four recipients: Dr. Mohamed Abou-el-Enein ($300,000) for CAR-T cell therapies manufacturing platform, Dr. Saul Priceman ($275,000) for solid cancer treatment research, Dr. Shahab Asgharzadeh ($250,000) for pediatric solid tumor therapy development, and Dr. Preet Chaudhary ($200,000) for solid tumor treatment research. The G-Rex Grant Program has made nearly 200 awards to date and has been extended with additional funding. Recipients gain access to ScaleReady's consortium of partners providing expertise in cGMP manufacturing, quality control, and regulatory affairs.

Bio-Techne (NASDAQ: TECH) will showcase its latest innovations at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting in New Orleans from May 13-17. Key highlights include the new RNAscope™ protease-free workflow for AAV vector visualization, ProPak™ GMP cytokines in dose-optimized bags, and the next-generation Simple Western Leo™ System capable of processing 100 samples in 3 hours.

The company will host a symposium on May 14th featuring presentations from industry leaders, including speakers from Dyno Therapeutics and Tessera Therapeutics. An additional talk on protein quantitation applications will be held on May 15th with speakers from Sangamo Therapeutics and Nervosave Therapeutics.

Bio-Techne (NASDAQ: TECH) and Kytopen have announced a partnership to enhance cell therapy manufacturing through integrated cellular engineering workflow. The collaboration combines Bio-Techne's TcBuster™ GMP non-viral genome engineering system with Kytopen's Flowfect Tx™ GMP cellular engineering platform.

The TcBuster™ system enables simultaneous delivery of multiple genes with high editing efficiency in a single vector, while Flowfect® technology processes billions of cells in minutes using a combination of mechanical, electrical, and chemical forces. Together, these technologies aim to streamline gene delivery processes and accelerate the development of advanced cell therapies.

The companies will present their collaborative data at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting in New Orleans, May 7-10, 2025.

Bio-Techne Corporation (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. Investors and interested parties can access a live webcast of the presentation through Bio-Techne's Investor Relations website, specifically on the IR Calendar page.

Bio-Techne (NASDAQ: TECH) has announced two significant shareholder returns initiatives. The company declared a quarterly dividend of $0.08 per share, payable on May 30, 2025, to shareholders of record as of May 19, 2025. Additionally, the Board approved a new $500 million share repurchase program effective May 8, 2025, replacing the previous program.

The timing and volume of share repurchases will be determined by various factors including share price, market conditions, and regulatory requirements. Bio-Techne, a global life sciences company providing research and clinical diagnostic tools, reported $1.2 billion in net sales for fiscal 2024 and employs approximately 3,100 people worldwide.

Bio-Techne (NASDAQ: TECH) reported its Q3 FY2025 financial results with organic revenue growth of 6% to $316.2 million. The company's GAAP EPS decreased to $0.14 from $0.31 year-over-year, while adjusted EPS improved to $0.56 from $0.48. The Protein Sciences segment showed strong performance with 7% organic growth to $227.7 million, driven by improved pharma end market conditions. The Diagnostics and Spatial Biology segment grew 2% to $89.2 million. The company achieved an adjusted operating margin of 34.9%, up from 33.0% in the prior year, benefiting from profitability initiatives and volume leverage. However, GAAP operating margin declined to 12.2% from 22.1%, impacted by a non-recurring arbitration award.

ScaleReady has awarded a $300,000 G-Rex® Grant to A2 Biotherapeutics to support process development and evaluation of G-Rex for manufacturing cell therapies. The grant enables A2 to explore the G-CART process, a standardized workflow for CAR-T drug product manufacturing, developed by Cell Ready.

A2 will evaluate this platform for their proprietary Tmod™ platform, a dual-signal integrator system for cancer cell therapy targeting various solid tumor indications including colorectal, lung, pancreatic, and ovarian cancers. The G-Rex Grant Program, which has awarded nearly 200 grants with over 50 new applications pending, has been extended with millions in additional funding.